Brain+ A/S ("Brain+" or "the Company") announces new commitments from the company's existing shareholders to exercise warrants in the ongoing TO 2 warrant exercise and subscribe for new shares in the company. The new commitments received correspond to 12% of the total number of warrants and cover proceeds of approximately DKK 0.7 million. Total commitments received to date to exercise and provide guarantees now cover almost 50% of the total number of TO 2 warrants outstanding.

Five additional Brain+ share and warrant holders have provided firm and soft commitments to exercise 3 million warrants of series TO 2 to subscribe for shares in Brain+. In addition, one of the shareholders has undertaken to also subscribe for 500,000 new shares in Brain+ in the form of a guarantee commitment of DKK 0.1 million The guarantee commitment will be activated if not all warrants are exercised in the ongoing TO 2 exercise. Should the guarantee commitments be activated, the company will make a directed share issue to the parties who gave the guarantee commitments at a subscription price equal to the exercise price of the warrants. No compensation will be paid for guarantee commitments.

The new commitments received secure Brain+ additionally approximately DKK 0.7 million in gross proceeds, corresponding to approximately 12% of the maximum, and comes on top of the commitments previously communicated by the company in a company announcement on 10 October 2023. Total commitments received to date in the ongoing exercise of warrants of series TO 2 now amounts to DKK 2.7 million, corresponding to almost 50% of the maximum gross proceeds being covered.

Summary of announced commitments in ongoing warrant exercise*

Name Committed Guarantee Total committed amount (DKK)
amount Amount
(DKK) (DKK)
Board & 208 618 196 982 405 600
Management
John Haurum 572 120 - 572 120
Commitments from 1,638,125 100,00 1,738,125
external
investors
Total (DKK) 2 418 862 296,982 2,715,845

*Includes commitments announced in this company announcement as well as those on 2 October, 10 October.

Summarized terms for the warrants of series TO2:

Exercise period: 2-16 October 2023
Exercise price: DKK 0.20
Last day of trading in 12 October 2023
warrants of series TO
2:
Issue volume: 28,542,348 warrants of series TO 2 which entitle to a
maximum subscription of 28,542,348 new shares. If all
warrants are exercised, the Company will receive
approximately DKK 5.7 million before issuing costs.
Dilution: Upon full exercise of warrants of series TO 2, the
number of shares of nominal value DKK 0.10 each will
increase by 28,542,348 shares from 44,262,866 shares
to 72,805,214 shares, and the share capital will
increase by DKK 2,854,234.80 from DKK 4,426,286.60 to
DKK 7,280,521.40. If all warrants of series TO 2 are
exercised, the dilution of the number of shares and
votes in the Company amounts to approximately 39
percent.

Complete terms and conditions for the warrants of series TO 2 can be found in the prospectus approved by the Danish Financial Supervisory Authority and published by the Company on 24 April 2023. The approved prospectus as well as additional informative documents, including a FAQ summary related to the exercise of warrants of series TO 2, is available on the Company's webpage (brain-plus.com) under Investor/Announcements and Financial Documents. The prospectus is also available on the Danish Financial Supervisory Authority's website (https://oam.finanstilsynet.dk).

Advisors
In connection with the unit rights issue including the issue and exercise of warrants of series TO 2, Sedermera Corporate Finance AB and Gemstone Capital A/S act as financial advisors to Brain+. Markets & Corporate Law Nordic AB act as legal advisor. Nordic Issuing AB is the issuing agent.

For more information about the warrant exercise, please contact:

Sedermera Corporate Finance AB
Phone: +46 (0) 40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se

Gemstone Capital A/S
Phone: +45 33 22 07 00

E-mail: sh@gemstonecapital.com

www.gemstonecapital.com 

For more information about Brain+, please contact:

Kim Baden-Kristensen, CEO
Phone: +45 31 39 33 17
E-mail: kim@brain-plus.com

www.brain-plus.com

Certified Adviser

Keswick Global AG

Phone: +43 1 740 408 045

E-mail: info@keswickglobal.com